



This itinerary of **Highlights for a General Audience** has been curated by the **Alzheimer's Association Medical and Scientific Relations team** to highlight the content that is most accessible to a **general audience**.

In addition to these highlights, **AAIC® For All** is a new extension of AAIC. A no-cost, single-day event, AAIC For All is an opportunity for clinicians and interested community members to learn about the latest research findings. AAIC For All takes place on the final day of AAIC, so you will be among the first to hear about cutting-edge research announced at the conference.

Sessions are listed in Eastern Daylight Time (Toronto, Canada).

Schedule is current at the time of posting. Titles are listed as submitted.

All sessions listed are hybrid and can be viewed live by both in-person and online attendees. Recordings will be available immediately and accessible to watch online for 30-days.

Plenary Sessions

Hear updates from the Alzheimer's Association and learn about the state of the field from a leading expert. All plenary sessions are in Hall ABC.

Date and Time	Session
Sunday, July 27 11:00 a.m.	Biomarker and Clinical Trajectories of Preclinical AD, Sylvia Villeneuve
Monday, July 28 11:00 a.m.	Neurovascular Interactions in Alzheimer's Disease: From Mechanisms to Treatments, Katerina Akassoglou The Multiple Facets of Tau Pathology, Maria Grazia Spillantini
Tuesday, July 29 11:00 a.m.	The Gut-Brain Axis in Alzheimer's Disease: Unraveling Pathogenesis and Exploring Novel Therapeutic Strategies, Inhee Mook-Jung Alzheimer's Disease in Down Syndrome, Juan Fortea
Wednesday, July 30 11:00 a.m.	Waking Up to the Importance of Sleep in MCI and AD, Sharon Naismith Restoring Hippocampal Glucose Metabolism Rescues Cognition Across Alzheimer's Disease Pathologies, Katrin Andreasson
Thursday, July 31 11:45 a.m.	Prevention of Dementia: A Necessary Worldwide Agenda, Gill Livingston Brain Resilience: Understanding Brain Aging and Neurodegeneration, Tony Wyss-Coray



AAIC for All Sessions - Community Track

You don't need to be a scientist to learn about the latest advances from the conference! Hear directly from the world's leading Alzheimer's and dementia scientists, clinicians and dementia professionals, including local Canadian-based researchers. Here more about the advances in research and the science that is giving us hope in this new era of treatment.

Date and Time	Session
Thursday, July 31 9:00 a.m Hall G	[AAIC For All] In The Neighborhood <ul style="list-style-type: none"> • Setting The Scene: Prevalence Of Alzheimer's And Dementia In Canada And Globally, Haung (Ho) Yu • The Clinical Prognosis Of Cognitively Unimpaired Individuals With Positive PET Biomarkers, Sylvia Villeneuve • Biofluid Biomarkers In Frontotemporal Lobar Degeneration (FTLD), Carmela Tartaglia • Brain Health Promotion With Métis People In Alberta: A Qualitative Study, Pamela Roach • Myelin Content In Older Individuals With Cerebral Small Vessel Disease: The Role Of Physical Activity And Lipids, Naron Boa Sorte Silva • Canada Community-University Partnerships For Successful Aging Research: The Canadian Superaging Research Initiative Site, Angela Roberts • Canada Exploring The Potential Of Virtual Reality And Artificial Intelligence As Tools To Design, Develop, And Deliver Psychotherapeutic Intervention For Family Caregivers Of Persons Living With Dementia, Mary Chiu
Thursday, July 31 10:00 a.m Hall G	[AAIC For All] AAIC 2025 Highlights <ul style="list-style-type: none"> • Breakthroughs In Early Detection Of Cognitive Impairment And Diagnosis, Heather Whitson • Recent Advancements In Treatment Approaches, Philip Scheltens • Insights Into Risk Reduction And Lifestyle Modification Strategies, Laura Baker • Latest Research On The Caregiving Experience, Nancy Hodgson • Alzheimer's Association Resources, Courtney Kloske

Scientific Sessions

Attend sessions and engage in live discussion.

Date, Time & Location	Session
Sunday, July 27 8:00 a.m. Room 801	<p>From Early-Life to Late-Life: The Role of Social and Environmental Factors in Cognitive Aging</p> <ul style="list-style-type: none"> • Changes in Loneliness, Social Isolation, and Social Support and Risk of Dementia: A Gender-Disaggregated Analysis of Community-Dwelling Older Adults, Htet Lin Htun • Predicting Accelerated and Delayed Aging in Global Settings: Biobehavioral Age Gaps and the Role of Global Exposomes, Hernan Hernandez • Association of Neighborhood Deprivation with Alzheimer's Disease Pathologies, Gray Matter Volume, White Matter Hyperintensities and Cognition by Sex, Race or Ethnicity and APOE4 Status in Non-Demented Older Adults, Pablo Aguilar • Early-Life Educational Experiences Moderates the Association Later-Life Glycemic Level and Memory Trajectories in Later-Life, A. Zarina Kraal • Racial/Ethnic Identity, Emotional Support and Late Life Cognition and Cognitive Decline After Age 90, Kazi Sabrina Haq
Sunday, July 27 9:00 a.m. Hall F	<p>Untangling the Relationship Between Neurodevelopmental Disorders, Cognitive Decline, and Alzheimer's Disease Risk</p> <ul style="list-style-type: none"> • Bridging Neurodevelopment and Neurodegeneration in Genetic Frontotemporal Dementia and Alzheimer's Disease, Suzee E. Lee • Examining Dementia Subtypes in a National Sample of Autistic Medicaid and Medicare Enrollees, Lindsay Shea • Reports of Elevated Cognitive Decline in Autistic Adults Are Linked to High Anticholinergic Potency, Gregory L. Wallace • Preliminary Findings and Feasibility of Mid-Life Cognitive and Blood-Based Biomarker Assessments in Adults with and without Prospectively Studied ADHD Diagnosis in Childhood, Brooke Molina • Alzheimer's Disease Genetic Risk Dosage and Verbal Memory in Autistic Adults, Samantha A. Harker
Sunday, July 27 4:15 p.m. Hall G	<p>A Half Century of Tau</p> <ul style="list-style-type: none"> • Regulation of Gene and Protein Expression by Toxic Tau, George S. Bloom • The Dual Role of Tau in Neuroprotection and Disease: Neuronal Senescence as a Therapeutic Target, Miranda E. Orr • Tau Protein and Neurodegeneration, Michel Goedert • Pharmacological Targeting of Tau-Induced Retrotransposon Activation, Bess Frost • Biofluid-Based Biomarkers for Tau Pathophysiology in Alzheimer's Disease, Kaj Blennow • Alzheimer's Disease Trajectory and the In Vivo Anatomy of Tau Progression, Keith A. Johnson
Sunday, July 27 4:15 p.m. Hall F	<p>Use of biomarkers in an era with anti-amyloid treatment</p> <ul style="list-style-type: none"> • Determining Eligibility for Anti-Amyloid Treatment, Barbara Joy Snider • Using (Digital) Biomarkers for Monitoring Disease Progression, Alina Solomon • Imaging Recommendations and Practice Considerations for ARIA Monitoring, Petrice M.

	<p>Cogswell</p> <ul style="list-style-type: none"> Using Biomarkers to Determine When to Stop Anti-Amyloid Treatment, Takeshi Iwatsubo
Sunday, July 27 4:15 p.m. Room 106	<p>Cognitive Reserve and Brain Resilience: The Role of Lifestyle, Diversity, and Early-Life Experiences in Aging and Dementia</p> <ul style="list-style-type: none"> Advancing Research on Diversity and Resilience in Aging and Dementia: Methodological Challenges and Roadmap Recommendations, Roger A. Dixon The Role of Hormonal and Reproductive Events on Cognitive Aging in a Cohort of Female Civil Servants: The Whitehall II Study, Shireen Sindi Integrative Discussion: Clinical Importance and Applied Potential of Including Diversity in Resilience Research, Prashanthi Vemuri Associations Between Early/Current Neighborhood Deprivation and Midlife Cognitive Functioning: Results from the Colorado Adoption/Twin Study of Lifespan Behavioral Development and Cognitive Aging (CATSLife), Elizabeth Muñoz The Role of Sex, Gender, and SSDH in Resilience Research, Gillian Einstein Social, Physical, and Cognitive Activity Patterns and Their Association with Tau and Amyloid Resistance and Resilience, Daniel Willie-Permor
Monday, July 28 9:00 a.m. Hall F	<p>Understanding and interpreting clinical meaningfulness of trial data in AD</p> <ul style="list-style-type: none"> Patient/Caregiver Perspective – Outcomes That Matter to Patients, Carla (DeMuro) Romano A Clinical Perspective on Meaningful Benefit, Ronald Petersen Clinical Relevance of Disease-Modifying Therapies for Alzheimer's Disease, Alette M. Wessels Conceptualizing Meaningful Between-Group Differences, Cheryl Coon
Monday, July 28 2:00 p.m. Hall ABC	<p>U.S. POINTER: Topline Results and Implications</p> <ul style="list-style-type: none"> U.S. POINTER: Study Design, Recruitment, and Baseline Participant Characteristics of a Large Multisite Multidomain Lifestyle Intervention Trial, Rachel A. Whitmer U.S. POINTER: Design of the Multidomain Lifestyle Interventions, Jeff Katula U.S. POINTER Study: Adherence to a Multidomain Health Behavior Change Intervention, Jennifer Ventrelle U.S. POINTER: Topline Results of a Large Multisite Randomized Controlled Multidomain Lifestyle Intervention Trial, Laura D. Baker Discussant: Joanne Pike
Monday, July 28 2:00 p.m. Room 801	<p>Global Solutions for Dementia Prevention: The Role of Online Educational Programs, Coaching, and Interventional Trials</p> <ul style="list-style-type: none"> Brain Health PRO: Evaluating a Web-Based Multidomain Intervention to Improve Dementia Literacy and Self-Efficacy, Sylvie Belleville A Web-Based Multidomain Intervention Improves Modifiable Risk Factors for Alzheimer's Disease, Haakon B. Nygaard Maintain Your Brain: Recent Findings, Future Challenges, Henry Brodaty Protect AD: Realizing New Clinical Trial Possibilities, Clive G. Ballard
Monday, July 28 4:15 p.m. Room 107	<p>Sensory Abnormalities in Dementia</p> <ul style="list-style-type: none"> Sex Differences in the Relationship Between Hearing Status and Cognitive Performance in Individuals with Mild Cognitive Impairment, Natalie A. Phillips Olfactory Impairment in Persons Living with Dementia, Alex Bahar-Fuchs

	<ul style="list-style-type: none"> • Practical Approaches to Identifying & Addressing Hearing Loss Among Persons Living with Dementia, Carrie L. Nieman • Non-verbal Dichotic Listening: A New, Cross-Cultural Central Hearing Test for Dementia, Chris JD Hardy • Associations Between Isolated and Combined Olfactory Dysfunction and Cognitive Impairment with Future Dementia in Community-Dwelling Older Adults, Javier Oltra • Autonomic and Neurosensory Disorders in Mild Cognitive Impairment and Dementia with Lewy Bodies Subjects: Characteristics, Follow-Up and Neural Basis, Morgane Linard
Tuesday, July 29 2:00 p.m. Hall F	Evidence-Based Clinical Practice Guidelines for Detection and Diagnosis of Cognitive Impairment using Blood-based Biomarkers and Cognitive Testing: Two Guideline Initiatives from the Alzheimer's Association
Tuesday, July 29 2:00 p.m. Room 107	<p>Language as a Lens: Investigating Cognitive Processes Across Linguistic Contexts</p> <ul style="list-style-type: none"> • Digits Across Languages: The Role of Lexical and Numerical Characteristics in Digit Span Performance Across Fourteen Languages, Boon Lead Tee • Cross-Linguistic Characterization of Speech and Language Profiles of English, Chinese, and Italian Primary Progressive Aphasia Patients: A Data-Driven Approach, Gaia Chiara Santi • Speech Timing Metrics as Cross-Linguistic Markers of Alzheimer's and Cognitive Decline: Evidence from Kiswahili, Spanish, and Portuguese Speakers, Adolfo M. Garcia • Patterns of Breakdown of Reading and Spelling in a Non-Alphabetic Language: A Study in Bengali, Amitabha Ghosh • Bilingualism and Naming in MCI and Alzheimer's Disease: Insights from Catalan-Spanish Speakers, Marco Calabria
Tuesday, July 29 4:15 p.m. Hall ABC	<p>Women's brain health across the lifespan: insights into aging and dementia</p> <ul style="list-style-type: none"> • Women in ADRD: Addressing Disparities in Diagnosis and Care, Tamlyn J. Watermeyer • Unveiling the X Chromosome's Role in Alzheimer's Disease, Rachel F. Buckley • Understanding the Intersection of Women's Health and Dementia Risk, Walter A. Rocca • Sex and Gender Differences in Cognitive Resilience, Eider M. Arenaza-Urquijo
Wednesday, July 30 8:00 a.m. Hall F	<p>The range of economic impacts of dementia</p> <ul style="list-style-type: none"> • Estimated Effects of Onset of Dementia on Labor Market, Maria Prados • Tracking the Economic Burden of Dementia: Changes in Care Costs and Spending Elasticity Relative to GDP and Per Capita Health Expenditure, Yue Dong • Employment, Volunteering, and Health-Related Resource Use in Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study, Carolyn W. Zhu • Transformer Deep Learning Architectures for Health Economic Modelling of Novel Therapies for Alzheimer's Disease, Linus Jönsson • Can Primary Prevention of Alzheimer's Disease Be Cost-Effective?, Soeren Mattke • The Journey of the Patients with Dementia in the Peruvian Health System, Daniela Rossini Vilchez
Wednesday, July 30 2:00 p.m. Hall F	<p>Differential Diagnosis - If it's not Alzheimer's then what's next?</p> <ul style="list-style-type: none"> • Vascular Dementia, Eric E. Smith • Frontotemporal Dementia, Julio Rojas • Lewy Body Dementia, Maria Cecilia Fernández

	<p>LATE (Limbic-predominant Age-related TDP-43 Encephalopathy), Seyed A. Sajjadi</p> <ul style="list-style-type: none"> • Normal Pressure Hydrocephalus (NPH), David T. Jones
<p>Wednesday, July 30 4:15 p.m. Room 718</p>	<p>Anti-Tau Etalantug (E2814) with Lecanemab Therapy in Individuals with Dominantly Inherited Alzheimer's Disease: A First Look at Baseline Characteristics and Impact of 6-Month Lecanemab Treatment on Amyloid PET and Safety in the DIAN-TU-001 NexGen Trial</p> <ul style="list-style-type: none"> • DIAN-TU-001 Trial (Tau NexGen) Rationale and Enrollment Experience, Lon S. S. Schneider • Baseline Participant Characteristics in the DIAN-TU-001 Trial, Jorge J. Llibre-Guerra • Baseline Imaging Characteristics of Participants in the Phase II/III DIAN-TU-001 Tau NexGen Trial for Dominantly Inherited Alzheimer's Disease, Tammie L.S. Benzinger • Lecanemab in DIAD: 6-Month Amyloid PET Results from the DIAN-TU-001 Trial, Randall J. Bateman • Safety of Lecanemab After 6-Month Treatment in the DIAN-TU-001 Trial, Jin Zhou